Ocugen, Inc. · NASDAQ:OCGN
Ocugen — Investor Presentation (October 2019)
16 slides from Ocugen's investor presentation, Oct 3, 2019
Slide 1: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our business strategy, future results of operati
Slide 2: Company Highlights
Company Highlights Nasdaq-listed company as of September 30, 2019 Robust IP portfolio with 31 issued U.S. and foreign patents and 29 U.S. and foreign patent applications Strategic Partnership with CanSinoBIO for OCU400 Gene Therapy Co-Development & Manufacturing • • • 3 ©2019 Ocugen. All Rights Rese
Slide 3: Experienced Leadership Team
Experienced Leadership Team • • • Diverse experience in large pharma, signature biotech, and small companies Track record of success Brings large and small company learnings to Ocugen 4 ©2019 Ocugen. All Rights Reserved. Rasappa Arumugham, PhD Chief Scientific Officer Vijay Tammara, PhD Vice Preside
Slide 4: Pipeline
Orphan us oGVHD OCU300 NR2f3 Mutation-Associated Retinal Degeneration Orphan us CfP290 Mutation-Associated Retinal Degeneration Orphan us OCU400 NIVI-?-AAV Rhodopsin Mutation-Associated Retinal Degeneration OCU410 RO!<-IMV DryAMD > WetAMD > OCU200 tiiTl ld.l " • Tr no;,f<'p·in Diabetic Macular Edema
Slide 5: OCU300 for oGVHD: Unmet Need for Patients with Ocular Graft vs Host Disease
OCU300 for oGVHD: Unmet Need for Patients with Ocular Graft vs Host Disease (oGVHD) Rare Ocular Diseases ~60% of chronic graft vs. host disease patients will develop oGVHD • Autoimmune disease that occurs in allogeneic bone marrow transplant patients –Donor derived leukocytes attack recipient ocular
Slide 6: First Phase 3 Study With Orphan Drug Designation
First Phase 3 Study With Orphan Drug Designation Indication: Treatment of ocular discomfort and ocular redness in patients with oGVHD • • • Randomized, Double-Masked, Placebo-Controlled, Phase 3 Study 84-day study Key inclusion criteria: diagnosis of ‘definite’ oGVHD using the International Chronic
Slide 7: OcuNanoE Formulation Increases OCU300 Concentration in Lacrimal Gland
OcuNanoETM Formulation Drug Delivery System Increases OCU300 Concentration in Lacrimal Gland Mouse DED Model (Preclinical) Brimonidine Level in Lacrimal Gland (Preclinical) ** 1 0 0 0 4 3 1 0 0 2 1 1 0 0 0 3 6 9 1 2 O C U 3 0 0 B r i m o n i d i n e T im e ( h ) Drug distribution to lacrimal gland f
Slide 8: OCU300 has Compelling Value Proposition
OCU300 has Compelling Value Proposition Market Access Market Potential Physicians Patients • Spend 3 months in hospital after receiving bone marrow transplant • Potential to be first approved product in US market • Most exhibit symptoms while still under hematologist/ oncologist care • First and onl
Slide 9: Modifier Gene Therapy Has a Broader Impact
Modifier Gene Therapy Has a Broader Impact Modifier Gene Therapy: Introduce a functional gene to modify the expression of many genes, gene-networks and reset homeostasis. Modifier gene Gene Augmentation: Transfer functional version of a non-functional gene into the target cells. Normal gene X Cell w
Slide 10: OCU400 Rescues Vision Loss in Multiple Retinal Diseases
OCU400 Rescues Vision Loss in Multiple Retinal Diseases Human Disease: PDE6B associated RP Mouse Rhodopsin associated adRP Rho-/-Rhodopsin associated adRP RhoP23 H Enhanced S-cone syndrome rd7-/-PDE associated arRP rd10-/-Leber Congenital Amaurosis Cep290 (rd16) rd1-/-Models: ^ *Treated fundus photo
Slide 11: OCU400: Orphan Drug Designation NR2E3 Mutation-Associated Retinal Degeneration
OCU400: Orphan Drug Designation NR2E3 Mutation-Associated Retinal Degeneration Early stage disease OCU400 Single Injection (Intravitreal) 1 mo Baseline (Control) 1 mo after treatment Advanced stage disease OCU400 Single Injection (Intravitreal) 3 mo Baseline (Control) 1 mo after treatment 3 mo Basel
Slide 12: OCU400 Gene Therapy Manufacturing: Strategic Partnership with CanSinoBIO
OCU400 Gene Therapy Manufacturing: Strategic Partnership with CanSinoBIO CanSinoBIO • • • Publicly-listed on Hong Kong exchange (6185.HK) Biotech Company with market cap of approximately $1B State-of-the-art facilities with world class team CanSinoBIO to perform CMC development & manufacturing of cl
Slide 13: Lead Biologic OCU200: Tumstatin-Transferrin Fusion Protein
Lead Biologic OCU200: Tumstatin-Transferrin Fusion Protein Offering Benefits Beyond Anti-VEGF In-Vitro Laser-Induced Rat CNV Model In-Vivo Laser-Induced Mouse CNV Model 8 0 6 0 4 0 PBS Tumstatin OCU200 Avastin V e h i c l e E y le a O C U 2 0 0 O C U 2 0 0 + E y l e a * indicates p<0.05 when compare
Slide 14: Summary of Near-Term Milestones
Summary of Near-Term Milestones OCU300 ocular GVHD (small molecule) OCU200 Wet AMD, DME, DR (novel biologic) • Dec 2018: First Patient Dosed 2019-2020: Continue IND-Enabling Studies • 1H2020: Sample Size re-estimation • 2021: Target Phase 1/2a Clinical Trial • 2H2020: Estimated Topline Results of Fi
Slide 15: Contact
Contact Kelly Beck Vice President, Investor Relations & Administration kelly.beck@ocugen.com 16 ©2019 Ocugen. All Rights Reserved.
Slide 16: Kelly Beck
Kelly Beck Vice President, Investor Relations & Administration kelly.beck@ocugen.com BOCUGEN exw oswnstnaretaana. , a